Steigerwald Gordon & Koch Inc. Has $15.79 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Steigerwald Gordon & Koch Inc. raised its holdings in Johnson & Johnson (NYSE:JNJ) by 2.9% in the second quarter, Holdings Channel.com reports. The fund owned 108,016 shares of the company’s stock after acquiring an additional 3,040 shares during the quarter. Johnson & Johnson makes up about 1.9% of Steigerwald Gordon & Koch Inc.’s investment portfolio, making the stock its 24th largest position. Steigerwald Gordon & Koch Inc.’s holdings in Johnson & Johnson were worth $15,788,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Vantage Financial Partners LLC lifted its stake in Johnson & Johnson by 41.0% in the second quarter. Vantage Financial Partners LLC now owns 2,017 shares of the company’s stock valued at $295,000 after acquiring an additional 587 shares during the last quarter. Eubel Brady & Suttman Asset Management Inc. lifted its stake in shares of Johnson & Johnson by 26.8% in the second quarter. Eubel Brady & Suttman Asset Management Inc. now owns 135,532 shares of the company’s stock worth $19,809,000 after buying an additional 28,660 shares during the last quarter. Gryphon Financial Partners LLC lifted its stake in shares of Johnson & Johnson by 7.7% in the second quarter. Gryphon Financial Partners LLC now owns 14,547 shares of the company’s stock worth $2,126,000 after buying an additional 1,034 shares during the last quarter. Malaga Cove Capital LLC lifted its stake in shares of Johnson & Johnson by 57.2% in the second quarter. Malaga Cove Capital LLC now owns 2,530 shares of the company’s stock worth $370,000 after buying an additional 921 shares during the last quarter. Finally, Van Hulzen Asset Management LLC lifted its stake in shares of Johnson & Johnson by 1.0% in the second quarter. Van Hulzen Asset Management LLC now owns 173,481 shares of the company’s stock worth $25,356,000 after buying an additional 1,686 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Trading Down 1.5 %

Shares of Johnson & Johnson stock opened at $164.82 on Thursday. The firm has a market capitalization of $396.67 billion, a PE ratio of 10.28, a price-to-earnings-growth ratio of 2.71 and a beta of 0.53. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07 and a quick ratio of 0.85. The company’s fifty day moving average price is $158.79 and its two-hundred day moving average price is $153.93. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $168.85.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.71 by $0.11. The firm had revenue of $22.45 billion for the quarter, compared to analyst estimates of $22.33 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The business’s revenue for the quarter was up 4.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.80 EPS. On average, analysts expect that Johnson & Johnson will post 10.02 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th were issued a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.01%. The ex-dividend date of this dividend was Tuesday, August 27th. Johnson & Johnson’s payout ratio is 30.92%.

Insider Transactions at Johnson & Johnson

In other news, VP Robert J. Decker sold 5,635 shares of the company’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the sale, the vice president now owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.16% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on JNJ shares. Daiwa America cut shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 23rd. The Goldman Sachs Group reduced their price objective on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a research note on Friday, July 19th. TD Cowen reduced their price objective on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a research note on Thursday, July 18th. Morgan Stanley upped their target price on shares of Johnson & Johnson from $167.00 to $169.00 and gave the company an “equal weight” rating in a research note on Thursday, July 18th. Finally, Sanford C. Bernstein upped their target price on shares of Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. Seven equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus target price of $173.21.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.